Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Zai Lab
Zai Lab at ASCO 2025: Rafael G. Amado in an Illuminating Dialogue Exchange with PharmaShots 
Shots:  Recently, Zai Lab presented data from a Phase Ia/Ib study evaluating ZL‑1310, a DLL3 ADC, in patients with extensive‑stage small cell lung cancer, both as a monotherapy and in combination with atezolizumab  ZL‑1310 leverages TMALIN technology, enabling clinicians to deliver more targeted doses of chemotherapy to cancer cells, distinguishing the compound from current standard‑of‑care…
July 23, 2025
Next-Gen T Cell Engagers for Solid Tumors: Shaun Murphy in a Riveting Dialogue Exchange with PharmaShots
Shots:   Unlike hematologic malignancies, where the elimination of most or all tumor cells results in immunosuppression, making headways in solid tumors requires a new holistic approach when using T Cell Engagers  Abpro’s ABP-102/CT-P72, co-developed by Celltrion leverages a tetravalent format; bivalent for both HER2 and CD3  PharmaShots welcomes Shaun Murphy, Vice President, Nonclinical Research and…
July 21, 2025
Retrieving Olfactory Prowess: Rick Geoffrion from Cyrano Therapeutics in Conversation with PharmaShots 
Shots:  Recently, Cyrano Therapeutics signed a licensing agreement with Resyca, integrating its novel therapy for post-viral smell loss, CYR-064, with Resyca’s Soft Mist Nasal Spray Technology  PharmaShots welcomes Rick Geoffrion, President & CEO of Cyrano Therapeutics, in an illuminating dialogue exchange centered around CYR-064 and its role in treating post-viral hyposmia (smell loss)  Rick highlights…
July 14, 2025
Unlocking Approval: Sofie Berg from AbbVie in a Riveting Conversation with PharmaShots 
Shots:  AbbVie adds an eighth indication to Rinvoq’s label with the European Commission’s approval for treating adult patients with giant cell arteritis (GCA)  Sofie Berg, Therapeutic Area Head of International Immunology at AbbVie, in a conversation with PharmaShots, shares insights from the SELECT-GCA trial evaluating Rinvoq in GCA, highlighting both primary and secondary endpoints  Rinvoq…
July 9, 2025
Patient Insights: Jerry Kelleher in an Illuminating Conversation with PharmaShots 
Shots:  Abbott’s AVEIR DR is the first in the world dual-chamber leadless pacemaker  Jerry Kelleher, a clinical trial participant in the AVEIR DR study, shares his transformative journey with PharmaShots  Explore Jerry’s miraculous recovery with AVEIR DR, which helped enhance his quality of life   Saurabh: Jerry, can you take us back to life and describe…
July 7, 2025
Regeneron at ASH’24: Aafia Chaudhry in a Stimulating Dialogue Exchange with PharmaShots 
Shots:   Recently, Regeneron presented Odronextamab’s data in treating patients with different B-NHL subtypes (OLYMPIA studies) and marginal zone lymphoma (ELM-2 study)  Aafia Chaudhry, Vice President, Global Program Head for Hematology-Oncology at Regeneron, discusses Odronextamab’s ongoing studies as monotherapy and in combination to treat various malignancies  Aafia shares the upcoming PDUFA date on July 30th for…
July 2, 2025
Unlocking Approval: Christophe Piketty from Galderma in an Illuminating Conversation with PharmaShots 
Shots:   Backed by positive results from the P-III ARCADIA study, Galderma’s Nemluvio recently received approval from the US FDA for patients with moderate to severe atopic dermatitis  Nemluvio (nemolizumab) has previously been approved for the treatment of prurigo nodularis  Christophe Piketty, VP, Head of Innovation, Therapeutic Dermatology, Global Clinical Sciences, Galderma, highlighted insights from the…
June 30, 2025
Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots
Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots
Shots:  At ASH 2024, Regeneron shared data from the P-III exploratory cohort investigating the pozelimab and cemdisiran combination (poze-cemdi) in patients with paroxysmal nocturnal hemoglobinuria  The novel combination (poze-cemdi) achieved meaningful control of intravascular hemolysis compared to ravulizumab   PharmaShots welcomes Lorah Perlee, Vice President, Global Program Head, Hematology and Translational Sciences at Regeneron, for an…
June 23, 2025
Patient Characteristics Trends in CAR-T Therapies: Dr. Ira Zackon in a Stimulating Discussion with PharmaShots 
Shots:  In a retrospective study sourced from EHR data for DLBCL patients, groundbreaking insights were unearthed that could potentially shape the treatment landscape of CAR-T Therapies in DLBCL  Data from the 10-year study is divided into pre- and post-CAR-T eras to better reflect trends in patient demographics and disease progression  PharmaShots welcomes Dr. Ira Zackon,…
June 18, 2025
Standardizing DLBCL Treatment: Dr. John Burke in a Riveting Conversation with PharmaShots  
Shots:   In the five-year follow-up data from the randomized POLARIX study, where participants received R-CHOP with a placebo for polatuzumab (control arm) and Pola-R-CHP with a placebo for vincristine   The primary endpoint of the study was progression free survival, and the secondary endpoint was overall survival  PharmaShots welcomes Dr. John Burke from Rocky Mountain Cancer…
June 16, 2025
Load more